NifH | Positive control/quantitation standard Reference: AS01 021S Concentration: after adding 90 µl of milliQ water final concentration of this standard is 0.15 pmoles/ul and this reagent is ready to use and load on a gel.Protein standard buffer composition: Glycerol 10%, Tris Base 141 mM, Tris HCl 106 mM, LDS 2%, EDTA 0.51 mM, SERVA® Blue G250 0.22 mM, Phenol Red 0.175 mM, pH 8.5, 0.1mg/ml PefaBloc protease inhibitor (Roche), 50mM DTT.This standard is ready-to-load and does not require any additions or heating. It needs to be fully thawed and thoroughly mixed prior to using. Avoid vigorous vortexing, as buffers contain detergent. Following mixing, briefly pulse in a microcentrifuge to collect material from cap.This standard is stabilized and ready and does not require heating before loading on the gel. Please note that this product contains 10% glycerol and might appear as liquid but is provided lyophilized. Allow the product several minutes to solubilize after adding water. Mix thoroughly but gently Take extra care to mix thoroughly before each use, as the proteins tend to settle with the more dense layer after freezing.
Datopotamab Reference: HY-P99843 Datopotamab (CDP7657) is an antibody targeting to TROP2. Datopotamab can be used to synthesize Datopotamab deruxtecan (HY-141598), TROP2-directed antibody-drug conjugate (ADC). Datopotamab deruxtecan consists of DNA topoisomerase I inhibitor Deruxtecan (HY-13631E) and Datopotamab.
AtpB | Positive control/quantitation standard Reference: AS03 030S Concentration: after adding 90 µl of dest. water final concentration of the standard is 0.27 pmol/µl.Protein standard buffer composition: Glycerol 10%, Tris Base 141 mM, Tris HCl 106 mM, LDS 2%, EDTA 0.51 mM, SERVA® Blue G250 0.22 mM, Phenol Red 0.175 mM, pH 8.5, 0.1mg/ml PefaBloc protease inhibitor (Roche), 50mM DTT.This standard is ready-to-load and does not require any additions or heating. It needs to be fully thawed and thoroughly mixed prior to using. Avoid vigorous vortexing, as buffers contain detergent. Following mixing, briefly pulse in a microcentrifuge to collect material from cap.This standard is stabilized and ready and does not require heating before loading on the gel. Please note that this product contains 10% glycerol and might appear as liquid but is provided lyophilized. Allow the product several minutes to solubilize after adding water. Mix thoroughly but gently Take extra care to mix thoroughly before each use, as the proteins tend to settle with the more dense layer after freezing.
Tafasitamab Reference: HY-P9981 Tafasitamab (XmAb5574) is an Fc-modified, humanized monoclonal antibody that binds to the human B-cell surface antigenCD19.
Anti-PsbB | CP47 protein of PSII Reference: AS04 038 This product can be sold containing ProClin if requestedin bis-tris gel systems PsbB protein migrates between 40-45 kDa
Cetrelimab Reference: HY-P99499 Cetrelimab (JNJ 63723283; JNJ 3283) is a humanized IgG4κ mAb targeting PD-1. Cetrelimab binds PD-1 (Kd=1.72 nM, HEK293) to block the interaction of PD-1 with PD-L1 and PD-L2 (IC50s=111.7 ng/mL and 138.6 ng/mL, respectively). Cetrelimab stimulates peripheral T cells, increases IFN-γ, IL-2, TNF-α level and inhibits tumor growth in vivo.
PsaC | PSI positive control/quantitation standard Reference: AS04 042S Protein standard buffer composition: Protein standard buffer composition: Glycerol 10%, Tris Base 141 mM, Tris HCl 106 mM, LDS 2%, EDTA 0.51 mM, SERVA® Blue G250 0.22 mM, Phenol Red 0.175 mM, pH 8.5, 0.1mg/ml PefaBloc protease inhibitor (Roche), 50mM DTT.
MDX-1342 Reference: HY-P99173 MDX-1342 is a fully human monoclonal antibody (HuMAb) of targeting CD19-membrane receptor. MDX-1342 can specifically bind to human CD19 antigen with high affinity and has antibody-dependent cellular cytotoxicity (ADCC) effect. MDX-1342 can be used for the research of B-lymphocyte malignancies and autoimmune.
Anti-AOX1/2 | Plant alternative oxidase 1 and 2 Reference: AS04 054 According to Konert et al. (2015) AOX antibody is recognizing AOX1A and AOX1D.This product can be sold containing ProClin if requested.
Rivabazumab pegol Reference: HY-P99954 Rivabazumab pegol is a PcrV protein antibody that can be used to study the phase II pegylated Fab of chronic Pseudomonas aeruginosa infection.
Anti-PsbD | D2 protein of PSII Reference: AS06 146 There is a confirmed cross-reaction with TLA1 protein in Chlamydomonas reinhardtii.For samples with a very low PSII content theremight be detection problems independent of the antibody. PSII proteins can vary in level depending upon liquid culture conditions. When the cells are in a stationary phase PSII content can drop to a very low level.
Ublituximab Reference: HY-P99538 Ublituximab (LFB-R603; TG-1101; TGTX-1101) is a next-generation, type 1 chimeric monoclonal antibody targeting a unique epitope on the CD20 antigen. Ublituximab has anticancer effects.